Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...

The move marks another escalation of the battle between Lilly and Novo Nordisk in the fast-growing obesity drugs market, where Zepbound is in a head-to-head contest with the latter's Wegovy ...

In common with Novo Nordisk’s semaglutide-based diabetes and obesity therapies – respectively Ozempic and Wegovy – Lilly has faced burgeoning demand for its therapies, despite which is ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. Let's figure out how Lilly could perform through the end of the decade, and decide whether ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. Lone Pine Capital, established in 1997 by Stephen Mandel, is a leading hedge ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

After hours: 7:59:31 pm GMT-5 ...